Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia

This publication has 102 references indexed in Scilit:

• CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance
  Cell Reports, 2013
• CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon Response
  Immunity, 2013
• Characterization of EHop-016, Novel Small Molecule Inhibitor of Rac GTPase
  Journal of Biological Chemistry, 2012
• Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
  Cancer Chemotherapy and Pharmacology, 2012
• Diverging fates of cells of origin in acute and chronic leukaemia
  EMBO Molecular Medicine, 2012
• Ran‐dependent nuclear export mediators: a structural perspective
  The EMBO Journal, 2011
• Stat5 is indispensable for the maintenance of bcr/abl‐positive leukaemia
  EMBO Molecular Medicine, 2010
• The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
  Proceedings of the National Academy of Sciences, 2007
• Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors
  Journal of Cell Biology, 2006
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
  Nature, 2005